SEATTLE--(BUSINESS WIRE)--Jun. 6, 2017--
Juno Therapeutics, Inc. (NASDAQ: JUNO) today announced that it will
webcast its presentation at the Goldman Sachs 38th Annual
Global Healthcare Conference at 10:00 a.m. PT on Tuesday, June 13, 2017.
The presentation will feature a business overview and update by Hans
Bishop, Juno’s President and Chief Executive Officer.
The webcast will be accessible on the Investor Relations page of Juno’s
website at www.JunoTherapeutics.com.
A replay of the presentation will be available at the same location for
30 days following the conference.
Juno Therapeutics is building a fully integrated biopharmaceutical
company focused on developing innovative cellular immunotherapies for
the treatment of cancer. Founded on the vision that the use of human
cells as therapeutic entities will drive one of the next important
phases in medicine, Juno is developing cell-based cancer immunotherapies
based on chimeric antigen receptor and high-affinity T cell receptor
technologies to genetically engineer T cells to recognize and kill
cancer. Juno is developing multiple cell-based product candidates to
treat a variety of B-cell malignancies as well as multiple solid tumors.
Several product candidates have shown compelling clinical responses in
clinical trials in refractory leukemia and lymphoma conducted to date.
Juno’s long-term aim is to leverage its cell-based platform to develop
new product candidates that address a broader range of cancers and human
diseases. Juno brings together innovative technologies from some of the
world’s leading research institutions, including the Fred Hutchinson
Cancer Research Center, Memorial Sloan Kettering Cancer Center, Seattle
Children’s Research Institute (SCRI), the University of California, San
Francisco, and The National Cancer Institute. Juno Therapeutics has an
exclusive license to the St. Jude Children’s Research Hospital patented
technology for CD19-directed product candidates that use 4-1BB, which
was developed by Dario Campana, Chihaya Imai, and St. Jude
Children’s Research Hospital. Juno’s product candidate JCAR017 was
developed in collaboration with SCRI and others.
This press release contains “forward-looking statements” within the
meaning of the Private Securities Litigation Reform Act of 1995, Section
27A of the Securities Act of 1933, and Section 21E of the Securities
Exchange Act of 1934, including statements regarding Juno’s mission,
progress, and business plans, Juno’s participation in the Goldman Sachs
38th Annual Global Healthcare Conference, and the subject
matter of Juno’s presentation at that conference. Forward-looking
statements are subject to risks and uncertainties that could cause
actual results to differ materially from such forward-looking
statements, and reported results should not be considered as an
indication of future performance. These risks and uncertainties include,
but are not limited to, risks associated with: the success, cost, and
timing of Juno’s product development activities and clinical trials;
Juno’s ability to obtain regulatory approval for and to commercialize
its product candidates; Juno’s ability to establish a
commercially-viable manufacturing process and manufacturing
infrastructure; regulatory requirements and regulatory developments;
success of Juno’s competitors with respect to competing treatments and
technologies; Juno’s dependence on third-party collaborators and other
contractors in Juno’s research and development activities, including for
the conduct of clinical trials and the manufacture of Juno’s product
candidates; Juno’s dependence on Celgene for the development and
commercialization outside of North America and China of Juno’s CD19
product candidates and any other product candidates for
which Celgene exercises an option; Juno’s dependence on JW Therapeutics
(Shanghai) Co., Ltd, over which Juno does not exercise complete control,
for the development and commercialization of product candidates
in China; Juno’s ability to obtain, maintain, or protect intellectual
property rights related to its product candidates; amongst others. For a
further description of the risks and uncertainties that could cause
actual results to differ from those expressed in these forward-looking
statements, as well as risks relating to Juno’s business in general, see
Juno’s Quarterly Report on Form 10-Q filed with the Securities and
Exchange Commission on May 4, 2017 and Juno’s other periodic reports
filed with the Securities and Exchange Commission. These forward-looking
statements speak only as of the date hereof. Juno disclaims any
obligation to update these forward-looking statements.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170606005443/en/
Source: Juno Therapeutics, Inc.
Juno Therapeutics, Inc.